Account
Publications
22.08.2024
ISPOR Europe 2024: Evaluating the Capabilities of ...

This study investigates the capabilities of AI tools including ChatGPT for conducting pricing and re...

Read more
07.08.2024
What does the right market access organisation str...

Effective pricing and market access (PMA) teams are vital for pharmaceutical companies to secure rei...

Read more
Insider Insights
23.07.2024
Saudi Arabia’s rise: from emerging market to...

The Saudi Food & Drug Authority (SFDA) released guidelines for Economic Evaluation Studies to assess...

Read more
Insider Insights
08.07.2024
New German Medicines Research Act: confidential re...

Germany's new Medicines Research Act allows confidential rebates for pharma companies, but recent am...

Read more
Articles
02.04.2024
Does price vs volume rule apply for CAR-Ts conside...

We explore CAR T-cell therapy challenges, regulatory approvals, market growth, pricing models, and a...

Read more
Publications
07.03.2024
World EPA Congress 2024: Implications of indicatio...

The study explores the complexities of pricing and reimbursement for multi-indication products in th...

Read more
News
13.02.2024
World EPA Congress 2024

The World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar...

Read more
Articles
08.02.2024
Is the attractiveness of launch in the UK changing...

This expert article focusses on the new proportionate approach, and the international recognition pr...

Read more
Publications
25.10.2023
ISPOR Europe 2023: Are Acute Therapies And Curativ...

We've updated our 2019 analysis which compares the annual and lifetime treatment costs of the 10 mos...

Read more
Publications
25.10.2023
ISPOR Europe 2023: Evaluation and Reimbursement of...

Our study compares and contrasts the evaluation and reimbursement pathways for digital therapeutics ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.